These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 7424016)

  • 1. [Aluminum-balance during haemodialysis (author's transl)].
    Graf H; Stummvoll HK; Kovarik J; Meisinger V; Wolf A; Pinggera WF
    Wien Klin Wochenschr; 1980; 92(11):391-4. PubMed ID: 7424016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Level-dependent inhibitory effect of hyperaluminaemia on parathyroid hormone secretion in patients with end-stage renal failure.
    Fernández E; Amoedo ML; Montoliu J
    Eur J Med; 1992 Dec; 1(8):482-4. PubMed ID: 1341207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect on serum aluminium levels of continued ingestion of aluminium gels by patients with chronic renal insufficiency (author's transl)].
    Boukari M; Rottembourg J; Jaudon MC; Clavel JP; Legrain M; Galli A
    Nouv Presse Med; 1978 Jan; 7(2):85-8. PubMed ID: 349501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Kinetics of aluminum absorption and serum concentration in chronic renal insufficiency].
    Sárszegi Z; Jobst K; Nagy J
    Orv Hetil; 2000 Aug; 141(35):1915-7. PubMed ID: 11019592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desferrioxamine-induced changes of aluminium kinetics during haemodialysis.
    Graf H; Stummvoll HK; Meisinger V
    Proc Eur Dial Transplant Assoc; 1981; 18():674-80. PubMed ID: 7329995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of aluminium on parathyroid hormone levels in haemodialysis patients.
    Cannata JB; Briggs JD; Junor BJ; Beastall G; Fell GS
    Proc Eur Dial Transplant Assoc; 1983; 19():244-7. PubMed ID: 6878239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aluminium load in patients with analgesic nephropathy.
    Schwarz A; Kraft D; Keller F; Gawlik D; Offermann G
    Miner Electrolyte Metab; 1987; 13(3):141-6. PubMed ID: 3627045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for aluminium accumulation in renal failure.
    Marsden SN; Parkinson IS; Ward MK; Ellis HA; Kerr DN
    Proc Eur Dial Transplant Assoc; 1979; 16():588-96. PubMed ID: 549003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prolonged and reversible encephalopathy in a chronic haemodialysis patient. Probable responsibility of aluminium salts (author's transl)].
    Buge A; Poisson M; Masson S; Bleibel JM; Lafforgue B; Raymond P; Jaudon MC
    Nouv Presse Med; 1978 Jun; 7(23):2053-9. PubMed ID: 673773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum aluminium in haemodialysis patients: relation to osteodystrophy, encephalopathy and aluminium hydroxide consumption.
    Heaf JG; Nielsen LP
    Miner Electrolyte Metab; 1984; 10(6):345-50. PubMed ID: 6503890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Aluminum poisoning in dialysis patients--diagnosis and therapy].
    Vogelsang U
    Schweiz Rundsch Med Prax; 1994 Jun; 83(24):738-56. PubMed ID: 8023059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aluminum, zinc and copper concentrations in plasma in chronic renal insufficiency.
    Zumkley H; Bertram HP; Lison A; Knoll O; Losse H
    Clin Nephrol; 1979 Jul; 12(1):18-21. PubMed ID: 477052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of zero magnesium dialysate and magnesium supplements on ionised calcium concentration in patients on regular dialysis treatment.
    Breuer J; Moniz C; Baldwin D; Parsons V
    Nephrol Dial Transplant; 1987; 2(5):347-50. PubMed ID: 3122112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Kinetics of plasma and urine aluminium after renal grafting (author's transl)].
    Hourmant M; Soulillou JP; Boiteau HL; Vecchierini MF; Métayer C; Guénel J
    Nephrologie; 1981; 2(3):125-9. PubMed ID: 7029337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Spontaneous fracture in a hemodialyzed woman probably associated with the oral intake of aluminium gel (author's transl)].
    Fournier G; Gaillard JL; Bourdon R; Drüeke T
    Nephrologie; 1981; 2(1):23-6. PubMed ID: 7345373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma aluminium levels in patients on maintenance haemodialysis fall when oral aluminium hydroxide is withdrawn.
    Wallace MR; Pybus J
    N Z Med J; 1983 Oct; 96(742):793-5. PubMed ID: 6578451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hyperaluminemia in chronic hemodialysis patients. Evaluation of the respective roles of dialysate aluminum and oral aluminum hydroxide].
    Tahiri Y; Moriniere P; Jaudon MC; Dkhissi H; Rosa A; Fournier A
    Nephrologie; 1983; 4(3):129-33. PubMed ID: 6633778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bullous dermatosis of end-stage renal disease: a possible association between abnormal porphyrin metabolism and aluminium.
    Gafter U; Mamet R; Korzets A; Malachi T; Schoenfeld N
    Nephrol Dial Transplant; 1996 Sep; 11(9):1787-91. PubMed ID: 8918623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Progressive myoclonic encephalopathy in dialysis patients. The role of the water used for haemodialysis (author's transl)].
    Cartier F; Allain P; Gary J; Chatel M; Menault F; Pecker S
    Nouv Presse Med; 1978 Jan; 7(2):97-102. PubMed ID: 652514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.